Skip to main content

Table 2 The 10-year overall survival (OS) and thalassemia-free survival (TFS) in the study population

From: The effect of bone marrow-derived mesenchymal stem cell co-transplantation with hematopoietic stem cells on liver fibrosis alleviation and survival in patients with class III β-thalassemia major

All patients OS (95% CI) P value TFS (95% CI) P value
Mesenchymal group No 61.89 (51.61–70.60) 0.294 52.78 (42.78–61.82) 0.285
Yes 71.84 (60.71–80.32) 63.64 (52.26–72.99)
Patient sex Female 72.09 (6088–8059) 0.131 67.94 (56.79–76.79) 0.245
Male 61.06 (51.04–69.63) 59.35 (349.52–58.44)
Donor sex Female 66.37 (54.58–75.77) 0.561 56.63 (45.15–66.59) 0.999
Male 65.78 (55.18–74.45) 57.66 (47.02–66.91)
Sex-matched Mismatched 62.57 (50.93–72.19) 0.458 50.76 (39.58–60.90) 0.098
Matched 68.72 (58.29–77.05) 62.93 (52.49–71.69)
ABO-matched ABO-matched 68.36 (58.15–76.58) 0.248 60.49 (50.36–69.19) 0.158
ABO-mismatched 62.17 (50.43–71.90) 51.65 (40.17–61.97)
Source of transplant BM 72.82 (61.29–81.43) 0.194 61.96 (50.18–71.73) 0.492
PB 62.21 (52.58–70.43) 54.45 (44.95–63.01)
Acute GvHD No 73.09 (62.21–81.30) 0.490 58.17 (47.36–67.51) 0.594
Yes 67.64 (59.42–71.51) 56.63 (46.41–65.62)
Chronic GvHD No 64.29 (58.13–70.17) 0.867 68.02 (59.27–76.23) 0.341
Yes 68.46 (59.19–76.39) 73.46 (61.19–82.39)
  1. OS overall survival, TFS thalassemia-free survival, GvHD graft-versus-host disease, BM bone marrow, PB peripheral blood
  2. Log-rank test